Todd R. Golub

This study evaluates strategies to inhibit XPR1 in ovarian cancer, showing that IP6K inhibitors effectively mimic XPR1 inhibition by blocking phosphate efflux and reducing tumor burden in xenograft models.

This study identifies IL13 as a survival factor for Hodgkin lymphoma cells by analyzing the tumor microenvironment with spatial and single-cell resolution.

The paper introduces SPICE, a framework that uses splicing assays and generative design to create cell-specific gene regulation elements for research and therapy.

The paper identifies O-mannosylation and protein maturation as therapeutic targets in BRAF fusion oncogenesis by showing their necessity for fusion-induced transformation.

This study identifies DNA hypomethylation, not DNA damage, as the primary mechanism of azacytidine and decitabine anti-cancer activity, linking it to chromatin regulators like USP48.

The paper identifies CD43 as a glyco-immune checkpoint that inhibits human macrophage phagocytosis, showing that O-linked glycosylation and sialylation pathways regulate this process in AML.

A DNA-binding agent increases cfDNA levels in blood, improving ctDNA detection and cancer sensitivity in mice.

A nanoparticle priming agent increases cfDNA levels in blood, improving ctDNA detection sensitivity in tumor-bearing mice.

The paper identifies DNA strand resynthesis as a source of false mutations in sequencing and introduces Duplex-Repair to reduce this error, improving sequencing accuracy.

MAESTRO enables efficient and accurate tracking of thousands of low-frequency mutations with reduced sequencing, improving mutation testing in cancer and liquid biopsies.

The paper improves gene dependency estimation from RNAi screens by using model-based normalization and data integration, enhancing accuracy and enabling cross-dataset analysis.

The paper creates a proteomic resource profiling 90 drugs in six cell lines, revealing cell-specific responses and enabling integration with transcriptional data to identify therapeutic opportunities.

The paper evaluates RNAi and CRISPR technologies by analyzing gene expression profiles in the Connectivity Map, finding that RNAi has strong off-target effects while CRISPR is more accurate.

The paper introduces the L1000 platform, a high-throughput gene expression profiling method, and reports 1.3 million perturbational profiles expanding the Connectivity Map for drug mechanism discovery and functional annotation.

The paper develops CERES, a computational method to correct copy-number effects in CRISPR-Cas9 essentiality screens, improving specificity in cancer cell line studies.